InvestorsHub Logo
Followers 4
Posts 1510
Boards Moderated 0
Alias Born 08/23/2010

Re: None

Wednesday, 06/21/2017 10:11:46 PM

Wednesday, June 21, 2017 10:11:46 PM

Post# of 13735
The reason we are here as shareholders is the efficacy of Sucanon in published scientific studies, which show that Sucanon works, and much better than many other oral diabetic medications.

Here is publicly verifiable information on previous Sucanon studies, which the FDA referred to as "substantial clinical investigations"

Preclinical in vitro tests of Sucanon (then diab2) in rat muscle showed an up regulation of insulin receptors
Sucanon outperformed biguanides (Metformin) and sulfonylureas (Glucotrol, Micronase, Amaryl) in rat models
Pharmacokinetics showed dose response relationship, peak response 2-4 hours, no effect by 10 hours
Toxicity: none at dosing 2000x therapeutic levels in dogs and rats with therapeutic index > 10,000, no carcinogenicity, teratogenicity, or mutagenicity in mice
Clinical studies: randomized double blind placebo controlled study in 370 adult type 2 diabetics, 6 months (1 month screening, 4 months treatment, 1 month post treatment) Sucanon outperformed Glyburide in control of fasting blood sugar levels, urinary glucose excretion, and glucose tolerance testing
(All above results done under management of Bob Rieveley, Biotech holdings, before involvement of FROI or ROTH current individuals)

Finally Dr Rojas study presented at EASD annual meeting 2013 in Barcelona Spain: 97 pre diabetic adult patients (HbA1C 5.7 to 6.2) 12 weeks with normalization of HbA1C (below 5.7) in 81% of study population and decrease in weight and visceral body fat, in contrast to weight gain in alternative medications. No "obvious conflict" of the researcher acting as a consultant to ROTH since any reputable professional organization allows researchers to present results at meetings when declaring a financial relationship or consultancy regarding the company or product.
The science is in fact done right, publicly verifiable and speaks for itself. The results of Sucanon testing, in addition to the risks of alternative treatments make Sucanon, IMO, an excellent first line choice for pre diabetic and non insulin dependent diabetics due to Sucanon's efficacy and safety. That is the reason I am involved as a shareholder. If this information is effectively communicated to prescribers and the burgeoning diabetic populations throughout the world (50% of population diabetic or prediabetic in USA alone and South Asia having some of the highest growth rates of diabetes in the world, the potential of Sucanon is enormous.
I'm pleased at the completion of the 12 week trial at ABC hospital in Mexico City to study Sucanon and satisfy any additional study requirements for the India regulatory application. The more Sucanon is studied, the more complete the verification of its safety and efficacy. FDA experts couldn't have said it better as these are indeed "substantial clinical investigations"

Beyond the science, it really gets down to whether the company is able to communicate the results of Sucanons efficacy through distribution in Mexico, Canada, and hopefully India pending review of results of the additional requested trial in Mexico. Can the company follow through on their goals of expanding to India while taking advantage of the HSBC financing agreement to increase sales in Mexico? If so ROTH will be an excellent investment. For me, the key issue is that scientifically Sucanon works. The rest is proper execution of the plans